No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Zhejiang Zhenyuan Share (000705.SZ): The equity structure of the controlling Shareholder has changed.
Gelonghui reported on February 10th that Zhejiang Zhenyuan Share (000705.SZ) announced that it recently received a notification from its controlling shareholder, Shaoxing Zhenyuan Health Industry Group Co., Ltd. (referred to as "Zhenyuan Health Group"), informing that the equity structure of Zhenyuan Health Group has changed, and it has obtained the "Business License" issued by the Shaoxing Municipal Market Supervision Administration. According to the "Implementation Plan for the Deepening and Enhancement Action of State-owned Enterprise Reform in Shaoxing City (2024-2025)" and the relevant requirements of the "Restructuring and Optimization Plan for State-owned Enterprises in Shaoxing City," Shaoxing State-owned Capital Operation Co., Ltd. (referred to as "Shaoxing State-owned Operation") will Hold Zhenyuan.
Zhejiang Zhenyuan: Zhejiang Zhenyuan Co., Ltd. 2024 Annual Performance Forecast
Zhejiang Zhenyuan Share (000705.SZ): Currently, there are no products produced for the treatment of influenza virus.
On January 10, Gelonghui reported that Zhejiang Zhenyuan Share (000705.SZ) stated on the investor interactive platform that the company's Pharmaceutical Sector produces antibiotics and anti-inflammatory painkillers for upper respiratory bacterial infections, and currently does not produce products for the treatment of influenza virus. Customers can visit Zhenyuan's affiliated stores and online mall to purchase related Pharmaceuticals as needed.
Zhejiang Zhenyuan Share (000705.SZ): Not involved in the silver-haired industry.
On January 10, Gelonghui reported that Zhejiang Zhenyuan Share (000705.SZ) stated on the investor interaction platform that the company's operation includes pharmaceutical distribution, pharmaceutical manufacturing, and health services, with the main business specifically consisting of the pharmaceutical commerce and pharmaceutical manufacturing sectors, and does not involve the silver industry.
Zhejiang Zhenyuan Share (000705.SZ): Currently, the biological project has launched the sterile culture linkage debugging.
Gelonghui reported on January 8 that Zhejiang Zhenyuan Share (000705.SZ) stated on the investor interaction platform that Zhenyuan Bio originally planned to move up the Engineering & Construction completion date to December 2024 and begin trial production. However, due to some equipment installation progress not meeting expectations, the project construction has been delayed. Currently, the biological project has initiated sterile culture linkage debugging.
Are Zhejiang Zhenyuan Share Co.,Ltd.'s (SZSE:000705) Mixed Financials Driving The Negative Sentiment?
